Journal: Emerging Microbes & Infections

Article Title: A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern

doi: 10.1080/22221751.2022.2149353

Figure Lengend Snippet: Construction and characterization of receptor-binding domain (RBD) protein and ASD254 nanoparticle vaccine. (A) Diagrammatic illustration of the SARS-CoV-2 spike protein and the recombinant RBD-His protein. The recombinant RBD protein consists of residues 319–541 of the SARS-CoV-2 spike protein of the Wuhan-Hu-1 isolate. The Igκ leader was added to the N-terminus of the RBD and a His6 tag was added to the C-terminus. (B) Validation of purified recombinant RBD protein. An amount of 3 μg of the purified recombinant RBD protein was used for SDS-PAGE and western blot analysis, with anti-RBD and anti-His antibody staining the purified recombinant RBD protein. (C) Flow cytometry of purified recombinant RBD binding against hACE2 and hDPP4. Purified recombinant RBD protein was incubated with parental, hACE2- or hDPP4-expressing 3T3 cells to test its binding capacity. The red line shows the binding of recombinant RBD protein with hACE2, the blue line shows the binding with hDPP4 and the gray shading shows the binding with parental 3T3 cells. (D) Diagram of the ASD254 nanoparticle and its composition. (E) Size distribution of ASD254 particles. (F) TEM image of ASD254. Scale bar, 500 nm. See also Figure S1.

Article Snippet: The SARS-CoV RBD protein (Sino Biological, Beijing), which also binds to hACE2 [ ], and MERS-CoV RBD protein (Sino Biological, Beijing), which binds to human dipeptidyl peptidase 4 (hDPP4) [ ], were included as controls.

Techniques: Binding Assay, Recombinant, Purification, SDS Page, Western Blot, Staining, Flow Cytometry, Incubation, Expressing

Journal: Drug Metabolism and Disposition

Article Title: Wuzhi Tablet ( Schisandra Sphenanthera Extract) Protects against Acetaminophen-Induced Hepatotoxicity by Inhibition of CYP-Mediated Bioactivation and Regulation of NRF2-ARE and p53/p21 Pathways

doi: 10.1124/dmd.114.059535

Figure Lengend Snippet: WZ possesses marked inhibitory effects on the activities of P450 enzymes and NAPQI-GSH formation. (A) Western blot analysis of CYP2E1, CYP1A2, CYP3A11, and glyceraldehyde-3-phosphate dehydrogenase levels in livers from control, WZ (700 mg/kg)-treated, APAP-treated, WZ (700 mg/kg)/APAP-treated mice. (B) Densitometric analysis of Western blots (n = 3). (C) Effect of WZ on the activities of CYP2E1, CYP1A2, CYP3A11 enzymes in mouse liver microsomes (n = 5). (D) Effect of WZ on NAPQI-GSH formation in mouse liver microsomes (n = 5). *P < 0.05, **P < 0.01, ***P < 0.001 versus control mice; #P < 0.05, ##P < 0.01 versus APAP-treated mice.

Article Snippet: CYP1A2 and CYP2E1 antibodies were purchased from Boster Biotechnology Co., Ltd. (Wuhang, China).

Techniques: Western Blot, Control

Journal: BMC Cancer

Article Title: Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker

doi: 10.1186/s12885-015-1757-0

Figure Lengend Snippet: CD26 serum levels in patients with gastric cancer ( n = 30) and in control healthy individuals ( n = 24). Patients serum CD26 levels: 557.7 ± 118.3 pg/mL; control serum CD26 levels: 703.4 ± 170.3 pg/mL. * p = 0.001 by unpaired t test

Article Snippet: The concentration of serum CD26 were analyzed using a specific immunoassays (Human CD26/DPP4 ELISA Kit, Boster biological technology, Pleasanton, CA) ELISAs were performed according to the manufacturer’s instructions: mean values of duplicated measurements were calculated and a sigmoid-shaped standard curve was determined by simultaneously analyzing a dilution series of standard samples.

Techniques: Control

Journal: Journal of Cellular and Molecular Medicine

Article Title: Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation

doi: 10.1111/jcmm.16122

Figure Lengend Snippet: Linagliptin improves left ventricular relaxation in obese ZSF1 rats. Plasma DPP‐4 activity (A), aGIP levels (B), fasting glucose levels (C), bodyweight (D), mitral valve deceleration time (E) and E/E’ ratio (F) in 20‐wk‐old linagliptin‐ (Obese + Lina) and placebo‐treated obese (Obese) ZSF1 rats (n = 7 per group). aGIP, active glucose‐dependent insulinotropic peptide; DPP‐4, dipeptidyl peptidase‐4; E, early mitral inflow peak velocity; E’, early diastolic mitral annulus peak velocity; ND, not detected; RFU, relative fluorescence units. Data are expressed as mean ± SEM. Data were analysed using a two‐tailed unpaired Student t test, except D was analysed by a Mann‐Whitney U test. * Indicates P < .05, ** P < .01 and *** P < .001

Article Snippet: Stripped tissue was incubated with (a) 300 ng/mL recombinant his‐tagged DPP‐4 (# 50718‐M08H; Sino Biological), (b) 300 ng/mL recombinant his‐tagged DPP‐4 and 100 nmol/L linagliptin (Boehringer Ingelheim GmbH) , or (c) PBS/DMSO (control) for 30 minutes to assess F passive in vitro.

Techniques: Activity Assay, Fluorescence, Two Tailed Test, MANN-WHITNEY

Journal: Journal of Cellular and Molecular Medicine

Article Title: Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation

doi: 10.1111/jcmm.16122

Figure Lengend Snippet: Linagliptin decreases F passsive by increasing titin phosphorylation at N2Bus S4010 in human cardiomyocytes in vitro. A, Cardiomyocyte passive stiffness in human cardiomyocytes treated with 300 ng/mL DPP‐4, 100 nmol/L linagliptin and 300 ng/mL DPP‐4, or control (DMSO/PBS) for 30 min (n = 3 different left ventricular tissues measuring at least 12 cardiomyocytes from each left ventricular tissue per condition). B, PKA‐mediated N2Bus S4010 phosphorylation and representative Coomassie Blue stained‐PVDF membranes and (C) PKG‐dependent N2Bus S4099 phosphorylation in human cardiomyocytes (n = 5 different left ventricular tissues) treated with vehicle control (DMSO/PBS), 300 ng/mL DPP‐4, 300 ng/mL DPP‐4 and 100 nmol/L linagliptin, or 100 nmol/L linagliptin for 2 h. F passive , passive stiffness; N2Bus, N2B unique sequence. Panel A was analysed using a two‐tailed unpaired Student t test with * P < .05. Panel B and C were analysed using a one‐way ANOVA with Dunnett's multiple comparison post hoc test with * P < .05 and *** P < .001 comparing control, DPP‐4 + Lina and Lina to DPP‐4

Article Snippet: Stripped tissue was incubated with (a) 300 ng/mL recombinant his‐tagged DPP‐4 (# 50718‐M08H; Sino Biological), (b) 300 ng/mL recombinant his‐tagged DPP‐4 and 100 nmol/L linagliptin (Boehringer Ingelheim GmbH) , or (c) PBS/DMSO (control) for 30 minutes to assess F passive in vitro.

Techniques: In Vitro, Staining, Sequencing, Two Tailed Test

Journal: Journal of Cellular and Molecular Medicine

Article Title: Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation

doi: 10.1111/jcmm.16122

Figure Lengend Snippet: Linagliptin prevents DPP‐4‐mediated titin cleavage in human cardiomyocytes in vitro. A‐B, Western blots of total titin, containing the two isoforms N2BA and N2B and the known degradation product titin‐2 (T2) of human intact non‐permeabilized (A) and non‐intact permeabilized (B) human cardiomyocytes exposed to control PBS/DMSO (Ctrl) for 0 or 2 h (lane 1 and 2, respectively), 300 ng/mL DPP‐4 for 30 min and 2 h (lane 3 and 4, respectively), 300 ng/mL DPP‐4 and 100 nmol/L linagliptin for 2 h (lane 5) or 100 nmol/L linagliptin alone for 2 h (lane 6) in vitro (n = 3 different left ventricular tissues). Titin cleavage is indicated by red asterisks. Western blots of the specific N2Bus region (C; cross‐species conserved sequence QELLSKETLFP) and PEVK region (D; cross‐species conserved sequence KLRPGSGGEKPP) of human cardiomyocytes exposed to control PBS/DMSO (Ctrl) for 0 or 2 h (lane 1 and 2, respectively), 300 ng/mL DPP‐4 for 30 min and 2 h (lane 3 and 4, respectively), 300 ng/mL DPP‐4 and 100 nmol/L linagliptin for 2 h (lane 5) or 100 nmol/L linagliptin alone for 2 h (lane 6) (n = 3 different left ventricular tissues). Titin cleavage is indicated by red asterisks. The framed area represents the location for the zoomed images presented on the right side. Ctrl, control; DPP‐4, dipeptidyl peptidase‐4; F passive , passive stiffness; Lina, linagliptin; N2Bus, N2B unique sequence. Data are expressed as mean ± SEM

Article Snippet: Stripped tissue was incubated with (a) 300 ng/mL recombinant his‐tagged DPP‐4 (# 50718‐M08H; Sino Biological), (b) 300 ng/mL recombinant his‐tagged DPP‐4 and 100 nmol/L linagliptin (Boehringer Ingelheim GmbH) , or (c) PBS/DMSO (control) for 30 minutes to assess F passive in vitro.

Techniques: In Vitro, Western Blot, Sequencing